JP2008513513A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513513A5
JP2008513513A5 JP2007532679A JP2007532679A JP2008513513A5 JP 2008513513 A5 JP2008513513 A5 JP 2008513513A5 JP 2007532679 A JP2007532679 A JP 2007532679A JP 2007532679 A JP2007532679 A JP 2007532679A JP 2008513513 A5 JP2008513513 A5 JP 2008513513A5
Authority
JP
Japan
Prior art keywords
decoy
seq
microemulsion
tissue
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532679A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513513A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/034110 external-priority patent/WO2006034433A2/en
Publication of JP2008513513A publication Critical patent/JP2008513513A/ja
Publication of JP2008513513A5 publication Critical patent/JP2008513513A5/ja
Pending legal-status Critical Current

Links

JP2007532679A 2004-09-21 2005-09-21 ポリヌクレオチドの送達 Pending JP2008513513A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61204604P 2004-09-21 2004-09-21
US66349705P 2005-03-18 2005-03-18
PCT/US2005/034110 WO2006034433A2 (en) 2004-09-21 2005-09-21 Delivery of polynucleotides

Publications (2)

Publication Number Publication Date
JP2008513513A JP2008513513A (ja) 2008-05-01
JP2008513513A5 true JP2008513513A5 (https=) 2009-03-05

Family

ID=36090693

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007532679A Pending JP2008513513A (ja) 2004-09-21 2005-09-21 ポリヌクレオチドの送達

Country Status (7)

Country Link
US (1) US20060069055A1 (https=)
EP (1) EP1799271A4 (https=)
JP (1) JP2008513513A (https=)
AU (1) AU2005286640A1 (https=)
CA (1) CA2583413A1 (https=)
MX (1) MX2007003167A (https=)
WO (1) WO2006034433A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US8241670B2 (en) * 2004-04-15 2012-08-14 Chiasma Inc. Compositions capable of facilitating penetration across a biological barrier
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US8530436B2 (en) * 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
AU2008224883A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
CA2723672C (en) * 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
JP5294302B2 (ja) * 2008-03-28 2013-09-18 マルホ株式会社 胸腺間質リンパ球増殖因子産生を評価するスクリーニング方法
CN102176900B (zh) 2008-09-17 2017-09-26 克艾思马有限公司 药物组合物和相关的给药方法
KR20140005998A (ko) * 2011-01-24 2014-01-15 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
CA2868391A1 (en) * 2012-04-02 2013-10-10 Stephane Bancel Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
EP3511022A1 (en) 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
HUE071943T2 (hu) 2015-02-03 2025-10-28 Amryt Endo Inc Akromegália kezelése oktreotid orális alkalmazásával
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
HRP20240477T1 (hr) * 2017-03-23 2024-07-05 Lipid Systems Sp. Z.O.O. Visoko učinkovito inkapsuliranje hidrofilnih spojeva u unilamelarne liposome
US12233073B2 (en) * 2017-06-09 2025-02-25 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
CA3128615A1 (en) * 2019-03-01 2020-09-10 Flagship Pioneering Innovations Vi, Llc Topical delivery of polyribonucleic acids
MA55083A (fr) * 2019-03-01 2022-03-16 Flagship Pioneering Innovations Vi Llc Polyribonucléotides et leurs utilisations cosmétiques
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
CN114469897B (zh) * 2022-01-12 2023-02-28 上海市胸科医院 靶向治疗心肌梗死的锂皂石复合递送材料及其制备与应用
US20230406888A1 (en) * 2022-04-27 2023-12-21 Sachi Bioworks Inc. Methods and systems for targeting autoimmune and inflammatory pathways using nanoligomers

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0824918B1 (en) * 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
DE69834038D1 (de) * 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
JP4215219B2 (ja) * 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
JP2002515514A (ja) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの局所送逹のための組成物及び方法
EP1080103A4 (en) * 1998-05-21 2003-07-02 Isis Pharmaceuticals Inc PREPARATIONS AND METHOD FOR THE NON-PARENTERAL ADMINISTRATION OF OLIGONUCLEOTIDES
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US6187587B1 (en) * 2000-03-02 2001-02-13 Isis Pharmaceuticals, Inc. Antisense inhibition of e2f transcription factor 1 expression
US20050203612A1 (en) * 2000-12-22 2005-09-15 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
JP4346233B2 (ja) * 2000-12-27 2009-10-21 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
TWI308492B (https=) * 2001-02-20 2009-04-11 Anges Mg Inc
US20050175539A1 (en) * 2001-11-22 2005-08-11 Ryuichi Morishita Compositions inhibiting rejection in organ transplantation and method of using the same
DE60231063D1 (de) * 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
AU2002241343A1 (en) * 2002-03-29 2003-10-13 Anges Mg, Inc. Decoy compositions for treating and preventing brain diseases and disorders
WO2003085110A2 (en) * 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
CA2493902A1 (en) * 2002-05-29 2003-12-04 Anges Mg, Inc. Decoy composition for treating and preventing inflammatory disease
AU2003303521A1 (en) * 2002-12-31 2004-07-29 Genta Incorporated Combination of gallium compounds with nonchemotherapeutic anticancer agents in the treatment of neoplasia
EP1462111A1 (en) * 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Composition for inducing immunotolerance
US20040191779A1 (en) * 2003-03-28 2004-09-30 Jie Zhang Statistical analysis of regulatory factor binding sites of differentially expressed genes
WO2005051229A2 (en) * 2003-11-24 2005-06-09 Avantec Vascular Corporation Devices delivering therapeutic agents and methods regarding the same
JP2007512845A (ja) * 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
EP1709175A2 (en) * 2003-12-03 2006-10-11 Corgentech, Inc. Hif oligonucleotide decoy molecules
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides

Similar Documents

Publication Publication Date Title
JP2008513513A5 (https=)
KR102623786B1 (ko) 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법
AU2014259755B2 (en) Compositions and methods for modulating apolipoprotein (a) expression
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
JP2018536689A5 (https=)
JP2018184423A5 (https=)
JP2010528041A5 (https=)
JP2012029693A5 (https=)
JP2019518037A (ja) Ｂ型肝炎感染症治療用のＰＡＰＤ５又はＰＡＰＤ７のｍＲＮＡ減少用核酸分子
JP2013510561A5 (https=)
JP2016502858A5 (https=)
JP2005512976A5 (https=)
HRP20191232T1 (hr) Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
JP2019525918A5 (https=)
JP2016513976A5 (https=)
TWI740866B (zh) 肽寡核苷酸結合物
ES3001019T3 (es) Inhibidores del MICRO-RNA 22
JP2014504857A5 (https=)
JP2006502243A5 (https=)
Mukai et al. Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney
JP2019523302A5 (https=)
US9492470B2 (en) Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells
JP6049143B2 (ja) オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター
JP2024530169A (ja) 方法
WO2017043639A1 (ja) キメラデコイ